CERO News

CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)

City of Quincy Partners with Cero Global to Launch Pilot Reducing Emissions and Fuel Costs

CERo Therapeutics Announces Trading on OTCQB Market

CERo Therapeutics Announces Receipt of Nasdaq Panel Determination

CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025

CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML